Gene panel predicts neoadjuvant chemoimmunotherapy response and benefit from immunotherapy in HER2-negative breast cancer
Our IP model shows favorable performance in predicting NACI response and is an effective tool for identifying BC patients who will benefit from ICIs. It may help clinicians optimize treatment strategies and guide clinical decision-making.
Authors
- H Chen (ORCID: https://orcid.org/0000-0003-4232-4153)
- Zongchao Gou (ORCID: https://orcid.org/0000-0002-9264-7586)
- Xun‐Xi Lu (ORCID: https://orcid.org/0000-0002-5118-0377)
- Li Li (ORCID: https://orcid.org/0000-0002-4499-9421)
- Fei Chen (ORCID: https://orcid.org/0000-0002-4346-6906)
- Hong Bu (ORCID: https://orcid.org/0000-0001-7472-6443)
- Chunjuan Bao
Institutions
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1136/jitc-2024-009587
- Citations
- 5
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.41
Funders
- Sichuan University
- Natural Science Foundation of Sichuan Province
- West China Hospital, Sichuan University